Arvest Bank Trust Division Buys Shares of 88,953 IQVIA Holdings Inc. (NYSE:IQV)

Arvest Bank Trust Division purchased a new position in shares of IQVIA Holdings Inc. (NYSE:IQVFree Report) in the third quarter, Holdings Channel.com reports. The firm purchased 88,953 shares of the medical research company’s stock, valued at approximately $21,079,000. IQVIA accounts for approximately 1.2% of Arvest Bank Trust Division’s holdings, making the stock its 26th largest holding.

Other large investors have also made changes to their positions in the company. Capital Performance Advisors LLP acquired a new stake in IQVIA in the third quarter valued at approximately $27,000. Park Place Capital Corp bought a new position in shares of IQVIA during the 3rd quarter valued at $28,000. Itau Unibanco Holding S.A. acquired a new stake in shares of IQVIA in the 2nd quarter valued at $29,000. International Assets Investment Management LLC acquired a new position in IQVIA during the second quarter worth $32,000. Finally, Avior Wealth Management LLC raised its holdings in IQVIA by 117.6% during the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after buying an additional 87 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. Morgan Stanley reduced their target price on IQVIA from $280.00 to $265.00 and set an “overweight” rating for the company in a report on Monday, November 4th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $270.00 price objective on shares of IQVIA in a report on Wednesday. JPMorgan Chase & Co. dropped their target price on shares of IQVIA from $279.00 to $240.00 and set an “overweight” rating on the stock in a report on Tuesday, November 5th. The Goldman Sachs Group decreased their price target on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a report on Friday, November 1st. Finally, William Blair reiterated an “outperform” rating on shares of IQVIA in a research note on Wednesday. Four analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $257.87.

View Our Latest Stock Report on IQVIA

IQVIA Stock Down 1.1 %

IQV opened at $201.05 on Thursday. IQVIA Holdings Inc. has a fifty-two week low of $187.62 and a fifty-two week high of $261.73. The company has a market capitalization of $36.49 billion, a P/E ratio of 26.38, a P/E/G ratio of 2.08 and a beta of 1.49. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. The firm’s fifty day moving average price is $214.01 and its two-hundred day moving average price is $224.77.

IQVIA Profile

(Free Report)

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Further Reading

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQVFree Report).

Institutional Ownership by Quarter for IQVIA (NYSE:IQV)

Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.